19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
01:35 , Feb 1, 2019 |  BC Week In Review  |  Company News

Ahead of 2019 milestones, Aslan reduces headcount, operating costs

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Jan. 29 it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on...
23:00 , Jan 29, 2019 |  BC Extra  |  Company News

Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on its...
17:34 , Jan 17, 2019 |  BC Week In Review  |  Clinical News

Aslan reports gastric, biliary tract cancer data for varlitinib

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said Jan. 14 that its pan-HER inhibitor varlitinib missed the primary endpoint of a Phase II trial to treat gastric cancer. The study evaluated varlitinib as a first-line therapy in...
15:08 , Jan 14, 2019 |  BC Extra  |  Clinical News

Aslan dips after Phase II gastric cancer miss

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said its pan-HER inhibitor varlitinib missed the primary endpoint of a Phase II trial to treat gastric cancer. Aslan shares slid $2.75 (10%) to $24.90 in Taipei on Monday, and...
07:06 , Dec 18, 2018 |  BC Extra  |  Politics & Policy

China outlines adjuvant drug list

China’s National Health Commission announced plans to create a national adjuvant drug list and guidelines that could limit the sales of those drugs. A notice released last week called for the establishment of a system...
21:26 , Nov 21, 2018 |  BC Extra  |  Company News

Management tracks: BerGenBio, Alzamend

BerGenBio ASA (OSE:BGBIO) said Clinical Development Officer Murray Yule will step down on Nov. 30. The cancer company hired former Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) leader Alan Barge as interim CMO. Barge...